

Mokslo diena 2022

Kviečiame atvykti į metų renginį, kuriame galėsite pamatyti ir daugiau sužinoti apie pasaulinio lyderio „Thermo Fisher Scientific“ produktus ir sprendimus gyvybės mokslams.
Dvejus metus Mokslo dienai vykus virtualiai, šį kartą galėsime vėl susitikti gyvai – lauksime jūsų Vilniaus universiteto Gyvybės mokslų centre (Saulėtekio al. 7).
Kita naujovė – šiemet Mokslo diena vyks kartu su Lietuvos biotechnologų asociacijos moksliniu simpoziumu „Genų redagavimas – nuo tyrimų iki pramonės“:
- nuo 9.30 min. iki pietų vyks Mokslo dienos pranešimai
- nuo 13 val. GMC prasidės genų redagavimui skirta konferencija, kurioje taip pat kviečiame dalyvauti – į ją reikalinga atskira registracija. Registraciją ir daugiau informacijos apie šį renginį rasite čia.
Visos dienos metu – nuo 8.30 min. iki 17 val. – vyks „Thermo Fisher Scientific“ Mokslo dienos paroda.
Renginyje pristatysime prekės ženklų „Invitrogen™“, „Thermo Scientific™“, „Applied Biosystems™“, „Gibco™“, „Ion Torrent™“ ir „Fisher Scientific™“ produktus, kurie skirti gyvybės mokslams ir kitiems laboratorijose atliekamiems tyrimams.
Renginyje taip pat turėsite galimybę daugiau išgirsti apie „Thermo Fisher Scientific“ karjeros galimybes .

Pranešėjai

Tadas Trunca
Thermo Fisher ScientificTITLE: Genomic Medicines: Past, Present and the Future
Biologic Therapies have been revolutionizing patient treatment in 20th and 21st centuries. The conventional biologics have successfully enabled healthcare to manage and treat multiple diseases globally. However, the adoption of next-generation biologics has been slowly getting momentum in the past decades. But the global tendencies have shifted significantly, especially during COVID-19 pandemic, and the world has seen huge focus and momentum in adoption of genomic medicines. How has biologics market evolved? Can genomic medicines replace traditional biologics drugs? What is the future of such genomic medicines as Oligo therapies, Cell & gene therapies and mRNA? We will glance at all of these questions together.
Eiva Bernotienė
Center for Innovative MedicineHead of Department of Regenerative Medicine, Chief Researcher at State Research Institute Centre for Innovative Medicine, Professor at VilniusTech University

Eiva Bernotienė
Center for Innovative MedicineTITLE: Emerging Cell-Based Technologies for the Treatment and Early Diagnosis of Cartilage Disorders
Prevalent cartilage disorders, including osteoarthritis, represent a highly unmet need in tools for early diagnosis and treatment. Osteoarthritis is a chronic debilitating joint disease, characterized by low-grade inflammation, degeneration of joint tissues such as articular cartilage, which has limited self-reparative capacity.
Aging, metabolic disorders, inadequate physical activity, trauma, comorbidities and their long-term treatment may gradually lead to deterioration of cartilage and osteoarthritis progression, which is still virtually impossible to adequately monitor and to which no effective cure is currently available.
However, the rapid progression of cell-based technologies is leading to innovative approaches addressing challenges in osteoarthritis management. Potential of tissue engineering, different types of stem cells, extracellular vesicles has been widely investigated, however with varying success so far. Emerging cell-based technologies currently under development or already on the way to implementation, as well as the main challenges in routine diagnostics, disease monitoring and therapy will be overviewed.
Jan Aleksander Krasko
National Cancer InstituteSenior Researcher at National Cancer Institute, Certifying Person, Head of the Laboratory at „Froceth“

Jan Aleksander Krasko
National Cancer InstituteTITLE: Cell Therapy Landscape in Lithuania: The Success Story
Cellular therapies are at the forefront of science, combining sophisticated cell manipulations, tissue engineering and genetic modifications. In the context of over 2000 clinical trials involving cell-based advanced therapeutic medicinal products (ATMPs) in Europe in the last decade, Lithuania has been making progress of its own, both in private and public sectors. There are several approved ATMP therapies on the market, GMP facilities being built, projects written and new products in development. Dendritic cells, cytokine induced killer T-cells, NK cells and, finally, CAR T-cells as well – Lithuanian scientists, technologists and regulatory specialists are at the top of their game.

Alessandra Romano
Thermo Fisher ScientificTITLE:
A Successful Journey through Cell and Gene Therapy: From R&D to Lot-Release
The presentation will be about the journey to produce a cell therapy, like CAR-T cells or a gene therapy. Thermo Fisher can support you from the very beginning in the research and development part and bring you successfully to scaling up and to manufacturing, providing all what you need from reagents to instruments. It is fundamental to characterize your product before going into patient and we will touch also this important topic.

Paulius Palaima
Thermo Fisher ScientificTITLE: More Convenient Nucleic Acid Analysis with the E-Gel™ Agarose Gel System
Horizontal nucleic acid electrophoresis is a cornerstone molecular biology technique. It has not changed much over the 50 years it has been in use – the agarose gel is laid in a buffer-filled tank, then samples are added and electric current turned on. From making the gel to obtaining results this process can take up to two hours.
E-Gel agarose gel electrophoresis system is a much more efficient use of the time. It offers a fast, convenient and safer way to analyze your nucleic acid samples. This is a dry-precast electrophoresis system, that eliminates the need for buffers or casting of gels. Together with the new E-Gel Power Snap Plus instrument it integrates electrophoresis, gel imaging and analysis into a one small device.

Kirsi Liimatainen
Thermo Fisher ScientificTITLE: How to store (mammalian) cells
Topics to be presented: Improving frozen (mammalian) cell viability & quality. Why cooling rate before actual storage temperature is important? Mycoplasma contamination in liquid nitrogen storage. Consequences of poor marking on tubes.

Andreas Koch
Thermo Fisher ScientificTITLE: KingFisher Devices and Applications
Do you want to do DNA/RNA/Protein and cell extraction with only one instrument? You want to have an open platform? Kit independent? With heating and cooling? Easy to use software for all applications? If so or only some parts of it, we have the solution for it. The KingFisher family gives all these applications with only one instrument, one software and a variety of kits for your choice. You can control each step of the extraction process by software and fine tune it to your needs. If you want to know more about so join us in the lunch session and visit our booth.
Programa
Dalyvių registracija ir rytinė kava/arbata
Paroda
Parodoje turėsite puikią progą pamatyti inovatyvią mokslinę, analitinę įrangą, stebėti jos demonstracijas, diskutuoti tiek su gamintojais, tiek su šių produktų platintojais Lietuvoje. Sužinosite daugiau apie prekės ženklų „Invitrogen™“, „Thermo Scientific™“, „Applied Biosystems™“, „Gibco™“, „Ion Torrent™“ ir „Fisher Scientific™“ produktus, kurie skirti gyvybės mokslams:
- Mėginių paruošimui
- Molekulinės biologijos tyrimams
- Baltymų biologijos tyrimams
- Ląstelių ir genų terapijos tyrimams
- Kitiems jūsų laboratorijose atliekamiems gyvybės mokslų tyrimams
Konferencijos atidarymas
Pranešimas: Genomic Medicines: Past, Present and the Future
Tadas Trunca
Biologic Therapies have been revolutionizing patient treatment in 20th and 21st centuries. The conventional biologics have successfully enabled healthcare to manage and treat multiple diseases globally. However, the adoption of next-generation biologics has been slowly getting momentum in the past decades. But the global tendencies have shifted significantly, especially during COVID-19 pandemic, and the world has seen huge focus and momentum in adoption of genomic medicines. How has biologics market evolved? Can genomic medicines replace traditional biologics drugs? What is the future of such genomic medicines as Oligo therapies, Cell & gene therapies and mRNA? We will glance at all of these questions together.
Pranešimas: Emerging Cell-Based Technologies for the Treatment and Early Diagnosis of Cartilage Disorders
Eiva Bernotienė
Prevalent cartilage disorders, including osteoarthritis, represent a highly unmet need in tools for early diagnosis and treatment. Osteoarthritis is a chronic debilitating joint disease, characterized by low-grade inflammation, degeneration of joint tissues such as articular cartilage, which has limited self-reparative capacity.
Aging, metabolic disorders, inadequate physical activity, trauma, comorbidities and their long-term treatment may gradually lead to deterioration of cartilage and osteoarthritis progression, which is still virtually impossible to adequately monitor and to which no effective cure is currently available.
However, the rapid progression of cell-based technologies is leading to innovative approaches addressing challenges in osteoarthritis management. Potential of tissue engineering, different types of stem cells, extracellular vesicles has been widely investigated, however with varying success so far. Emerging cell-based technologies currently under development or already on the way to implementation, as well as the main challenges in routine diagnostics, disease monitoring and therapy will be overviewed.
Pranešimas: Cell Therapy Landscape in Lithuania: The Success Story
Jan Aleksander Kraśko
Cellular therapies are at the forefront of science, combining sophisticated cell manipulations, tissue engineering and genetic modifications. In the context of over 2000 clinical trials involving cell-based advanced therapeutic medicinal products (ATMPs) in Europe in the last decade, Lithuania has been making progress of its own, both in private and public sectors. There are several approved ATMP therapies on the market, GMP facilities being built, projects written and new products in development. Dendritic cells, cytokine induced killer T-cells, NK cells and, finally, CAR T-cells as well – Lithuanian scientists, technologists and regulatory specialists are at the top of their game.
Pietūs
Renginio metu lankytojus vaišinsime kava ir užkandžiais, o 11:30-12:45 lankytojus pakviesime pasivaišinti nemokamais pietumis.
Lunch-on: paralelinių pranešimų sesija
Pranešimas 1: A Successful Journey through Cell and Gene Therapy: From R&D to Lot-Release
Alessandra Romano
The presentation will be about the journey to produce a cell therapy, like CAR-T cells or a gene therapy. Thermo Fisher can support you from the very beginning in the research and development part and bring you successfully to scaling up and to manufacturing, providing all what you need from reagents to instruments. It is fundamental to characterize your product before going into patient and we will touch also this important topic.
Pranešimas 2: More Convenient Nucleic Acid Analysis with the E-Gel™ Agarose Gel System
Paulius Palaima
Horizontal nucleic acid electrophoresis is a cornerstone molecular biology technique. It has not changed much over the 50 years it has been in use – the agarose gel is laid in a buffer-filled tank, then samples are added and electric current turned on. From making the gel to obtaining results this process can take up to two hours.
E-Gel agarose gel electrophoresis system is a much more efficient use of the time. It offers a fast, convenient and safer way to analyze your nucleic acid samples. This is a dry-precast electrophoresis system, that eliminates the need for buffers or casting of gels. Together with the new E-Gel Power Snap Plus instrument it integrates electrophoresis, gel imaging and analysis into a one small device.
Pranešimas 3: KingFisher Devices and Applications
Andreas Koch
Do you want to do DNA/RNA/Protein and cell extraction with only one instrument? You want to have an open platform? Kit independent? With heating and cooling? Easy to use software for all applications? If so or only some parts of it, we have the solution for it. The KingFisher family gives all these applications with only one instrument, one software and a variety of kits for your choice. You can control each step of the extraction process by software and fine tune it to your needs. If you want to know more about so join us in the lunch session and visit our booth.
Pranešimas 5: Karjeros galimybės „Thermo Fisher Scientific“
Eglė Mažeikė
Kviečiame studijuojančius ir visus, besidominčius karjera “Thermo Fisher Scientific” kompanijoje, daugiau išgirsti apie karjeros galimybes. Pristatysime ne tik atviras pozicijas, bet ir plačiau pristatysime įsidarbinimo galimybes įvairiose srityse: pradedant gamyba, moksliniais tyrimais ir baigiant kokybės užtikrinimo veikla. Studentams taip pat papsakosime apie praktikų programą bei galimybę gautis vardines stipendijas. Ir, aišku, atsakysime į jums rūpimus klausimus.
Mokslinis simpoziumas „Genų redagavimas: nuo tyrimų iki pramonės"
Šiemet Mokslo dienos vyks kartu su Lietuvos biotechnologų asociacijos moksliniu simpoziumu „Genų redagavimas – nuo tyrimų iki pramonės“, todėl nuo 13 val. kviečiame dalyvauti šioje konferencijoje.
Norint dalyvauti, prašome iš anksto registruotis čia: REGISTRACIJA
Registracija
Dalyvavimas renginyje – nemokamas. Kadangi vietų skaičius yra ribotas, registracija į jį yra būtina. Registracija pasibaigs užsipildžius vietoms arba iki 2022 m. spalio 23 d. imtinai.

Vieta
Konferencija vyks Gyvybės mokslų centre, Saulėtelio al. 7, Vilniuje.

Thermo Fisher Scientific
„Thermo Fisher Scientific“ yra pasaulinė lyderė, teikianti produktus ir paslaugas mokslui. Mūsų misija yra padėti klientams padaryti pasaulį sveikesnį, švaresnį ir saugesnį.
Tad nepriklausomai nuo to, ar mūsų klientai vykdo gyvybės mokslų tyrimus, sprendžia sudėtingas analitines užduotis, tobulina pacientų diagnostiką ir gydymą ar didina savo laboratorijų produktyvumą, esame pasirengę jiems padėti.
Mūsų komanda visame pasaulyje yra neprilygstama lyderė inovatyvių technologijų, patogaus pirkimo ir farmacijos paslaugų srityse, galinti didžiuotis tokiais prekės ženklais kaip „Thermo Scientific“, „Applied Biosystems“, „Invitrogen“, „Fisher Scientific“, „Unity Lab Services“, „Patheon“ ir PPD.
